Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: GlobeNewswire
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the year and quarter ended December 31, 2025. “The comp
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology (PYXS) had its price target lowered by Stifel Nicolaus from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Pyxis Oncology (PYXS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Pyxis Oncology GAAP EPS of -$1.28 misses by $0.93, revenue of $13.9M [Seeking Alpha]Seeking Alpha
- Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology (PYXS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PYXS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" tMarketBeat
PYXS
Earnings
- 3/23/26 - Miss
PYXS
Sec Filings
- 3/25/26 - Form 4
- 3/25/26 - Form 4
- 3/25/26 - Form 4
- PYXS's page on the SEC website